Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
A2DINOv3: Rethinking Multi-Modal Object Detection via Socialized Collaboration
arXiv:2608.21099v2 Announce Type: replace-cross Abstract: Multi-modal object detection is essential for robust scene understanding in challenging conditions, including low-light and adverse environments. Recent vision foundation models (e.g., DINOv3) have exhibited strong representation capabilities, yet adapting them to multi-modal scenarios remains challenging. Existing dense cross-modal fusion strategies often force heterogeneous modalities to interact indiscriminately, which may introduce r
-
Omics in Gastric
-
Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies
Biofactors. 2026 Sep-Oct;52(5):e70150. doi: 10.1002/biof.70150.ABSTRACTGastrointestinal malignancies, including gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, remain major causes of cancer-related morbidity and mortality worldwide. Although chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, its efficacy in gastrointestinal solid tumors remains limited by antigen heterogeneity, insuffic
Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies
Biofactors. 2026 Sep-Oct;52(5):e70150. doi: 10.1002/biof.70150.
ABSTRACT
Gastrointestinal malignancies, including gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, remain major causes of cancer-related morbidity and mortality worldwide. Although chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, its efficacy in gastrointestinal solid tumors remains limited by antigen heterogeneity, insufficient trafficking and infiltration, immunosuppressive tumor microenvironments, on-target off-tumor toxicity, and adaptive resistance. In this review, we summarize the current landscape of CAR-T therapy in gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer, with a focus on representative target antigens and emerging biomarker strategies. We further discuss two major categories of biomarkers: target antigen-related biomarkers and conventional dynamic biomarkers, including serum tumor markers, cytokine changes, CAR-T expansion kinetics, and antigen-loss monitoring. In addition, we highlight how single-cell ribonucleic acid sequencing and spatial transcriptomics provide complementary insights into cellular states, immune exhaustion, stromal barriers, and spatially restricted immune exclusion. By integrating these multi-omics approaches with biomarker-guided patient stratification and next-generation CAR-T engineering, gastrointestinal solid tumor CAR-T therapy may evolve from empirical optimization toward mechanism-driven and precision-guided clinical translation.
PMID:42717494 | PMC:PMC13558850 | DOI:10.1002/biof.70150